低临床与基因组风险乳腺癌患者保乳术后省略放疗:IDEA研究5年结果
IDEA单臂试验前瞻性纳入200例50-69岁绝经后pT1N0浸润性乳腺癌患者,保乳术后根据经典临床病理因素联合Oncotype DX 21基因复发评分≤18选择省略放疗并接受至少5年内分泌治疗。中位随访至少56个月的186例患者5年总生存率和乳腺癌特异性生存率均为100%,5年无任何复发率为99%(95%CI 96-100)。
要点
- 50-69岁pT1N0且Oncotype DX复发评分≤18的绝经后患者,保乳术后省略放疗联合内分泌治疗5年无复发率99%。
- 50-59岁与60-69岁患者同侧乳腺事件粗率分别为3.3%(2/60)与3.6%(5/140)。
- 50-59岁与60-69岁患者总体复发粗率分别为5.0%(3/60)与3.6%(5/140)。
核心结论
- 在经典临床和生物学特征基础上联合基因组检测进行选择,包括60岁以下绝经后患者,本试验实现了极低的复发风险。
- 本试验及其他试验的长期随访将有助于确定是否可向比现行指南推荐更广泛的人群提供避免初始放疗的选择。
研究设计与样本
- 单臂前瞻性试验,于2015年6月至2018年10月入组200例符合条件的绝经后患者。
- 入组条件为年龄50-69岁、pT1N0单灶浸润性乳腺癌、保乳术后切缘≥2 mm、雌激素受体阳性、孕激素受体阳性、人表皮生长因子受体2阴性且Oncotype DX 21基因复发评分≤18,并同意接受至少5年内分泌治疗。
- 主要终点为保乳术后5年局部区域复发率。
主要发现
- 186例临床随访至少56个月的患者5年总生存率和乳腺癌特异性生存率均为100%。
- 5年无任何复发率为99%(95%CI 96-100)。
- 50-59岁患者同侧乳腺事件粗率为3.3%(2/60),60-69岁患者为3.6%(5/140)。
- 50-59岁患者总体复发粗率为5.0%(3/60),60-69岁患者为3.6%(5/140)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需本试验及其他试验的长期随访,以确定是否可向比现行指南推荐更广泛的人群提供避免初始放疗的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple studies have shown a low risk of ipsilateral breast events (IBEs) or other recurrences for selected patients age 65-70 years or older with stage I breast cancers treated with breast-conserving surgery (BCS) and endocrine therapy (ET) without adjuvant radiotherapy. We sought to evaluate whether younger postmenopausal patients could also be successfully treated without radiation therapy, adding a genomic assay to classic selection factors. METHODS: Postmenopausal patients age 50-69 years with pT1N0 unifocal invasive breast cancer with margins ≥2 mm after BCS whose tumors were estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2-negative with Oncotype DX 21-gene recurrence score ≤18 were prospectively enrolled in a single-arm trial of radiotherapy omission if they consented to take at least 5 years of ET. The primary end point was the rate of locoregional recurrence 5 years after BCS. RESULTS: Between June 2015 and October 2018, 200 eligible patients were enrolled. Among the 186 patients with clinical follow-up of at least 56 months, overall and breast cancer-specific survival rates at 5 years were both 100%. The 5-year freedom from any recurrence was 99% (95% CI, 96 to 100). Crude rates of IBEs for the entire follow-up period for patients age 50-59 years and age 60-69 years were 3.3% (2/60) and 3.6% (5/140), respectively; crude rates of overall recurrence were 5.0% (3/60) and 3.6% (5/140), respectively. CONCLUSION: This trial achieved a very low risk of recurrence using a genomic assay in combination with classic clinical and biologic features for treatment selection, including postmenopausal patients younger than 60 years. Long-term follow-up of this trial and others will help determine whether the option of avoiding initial radiotherapy can be offered to a broader group of women than current guidelines recommend.
引用
- Jagsi R, Griffith KA, Harris EE, et al. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. J Clin Oncol. 2023. PMID: 38060195. doi:10.1200/JCO.23.02270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。